| 1 | | - | SENATE RESOLUTION NO. 30 Senators Santana, Geiss and McMorrow offered the following resolution: A resolution to designate May 4-10, 2025, as Tardive Dyskinesia Awareness Week. Whereas, Serious mental illnesses such as bipolar disorder, major depressive disorders, and schizophrenia require treatment with antipsychotic medications for effective management, while antipsychotic prescribing rates continue to rise; and Whereas, While prolonged antipsychotic use may be essential for the treatment of certain conditions, it is often associated with tardive dyskinesia (TD), a condition marked by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, or extremities; and Whereas, Those at a higher risk of TD include individuals older than 55, Black individuals, women, individuals with mood or substance use disorders, intellectual disabilities, or central nervous system injuries, and those with high cumulative antipsychotic exposure; and Whereas, Approximately 60 percent of the estimated 800,000 American adults living with TD remain undiagnosed; and Whereas, Even mild TD symptoms can be stigmatizing and impair physical, social, and emotional well-being, underscoring the urgency of early screening, detection, and intervention; and Whereas, The American Psychiatric Association recommends routine TD screening in their clinical guidelines for antipsychotic treatment. Individuals treated with antipsychotics or experiencing abnormal movements should consult their healthcare providers to assess TD risk, receive TD screenings, and determine appropriate treatment together; and Whereas, FDA-approved treatments for TD can provide options for symptom management and improved quality of life for many individuals living with TD; and Whereas, We encourage TD screening education and awareness for health care providers, patients, and care partners to help ensure patients prescribed antipsychotics receive care and support that aligns with clinical best practices, including regular TD screenings; now, therefore, be it Resolved by the Senate, That the members of this legislative body designate May 4-10, 2025, as Tardive Dyskinesia Awareness Week; and be it further Resolved, That we encourage anyone experiencing uncontrollable, abnormal, and repetitive movements to consult their healthcare provider regarding their symptoms. |
|---|
| 1 | + | SENATE RESOLUTION NO. 30 Senator Santana offered the following resolution: A resolution to designate May 4-10, 2025, as Tardive Dyskinesia Awareness Week. Whereas, Serious mental illnesses such as bipolar disorder, major depressive disorders, and schizophrenia require treatment with antipsychotic medications for effective management, while antipsychotic prescribing rates continue to rise; and Whereas, While prolonged antipsychotic use may be essential for the treatment of certain conditions, it is often associated with tardive dyskinesia (TD), a condition marked by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, or extremities; and Whereas, Those at a higher risk of TD include individuals older than 55, Black individuals, women, individuals with mood or substance use disorders, intellectual disabilities, or central nervous system injuries, and those with high cumulative antipsychotic exposure; and Whereas, Approximately 60 percent of the estimated 800,000 American adults living with TD remain undiagnosed; and Whereas, Even mild TD symptoms can be stigmatizing and impair physical, social, and emotional well-being, underscoring the urgency of early screening, detection, and intervention; and Whereas, The American Psychiatric Association recommends routine TD screening in their clinical guidelines for antipsychotic treatment. Individuals treated with antipsychotics or experiencing abnormal movements should consult their healthcare providers to assess TD risk, receive TD screenings, and determine appropriate treatment together; and Whereas, FDA-approved treatments for TD can provide options for symptom management and improved quality of life for many individuals living with TD; and Whereas, We encourage TD screening education and awareness for health care providers, patients, and care partners to help ensure patients prescribed antipsychotics receive care and support that aligns with clinical best practices, including regular TD screenings; now, therefore, be it Resolved by the Senate, That the members of this legislative body designate May 4-10, 2025, as Tardive Dyskinesia Awareness Week; and be it further Resolved, That we encourage anyone experiencing uncontrollable, abnormal, and repetitive movements to consult their healthcare provider regarding their symptoms. |
|---|